Evidence map›Paper›PMID 32214327›Full record

ArticlePloS one2020

Characterisation of ACP5 missense mutations encoding tartrate-resistant acid phosphatase associated with spondyloenchondrodysplasia.

Janani Ramesh, Latha K Parthasarathy, Anthony J Janckila, Farhana Begum, Ramya Murugan, Balakumar P S S Murthy, Rif S El-Mallakh, Ranga N Parthasarathy, Bhuvarahamurthy Venugopal

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. CombiningFrontiers in cell and developmental biology · 2025
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Janani RameshDepartment of Medical Biochemistry, Dr. ALM-PGIBMS, University of Madras, Madras, India.
Latha K ParthasarathyDepartment of Psychiatry, University of Louisville School of Medicine, Louisville, KY, United States of America.
Anthony J JanckilaDepartment of Microbiology and Immunology, University of Louisville, School of Medicine, Louisville, KY, United States of America.
Farhana BegumDepartment of Medical Biochemistry, Dr. ALM-PGIBMS, University of Madras, Madras, India.
Ramya MuruganDepartment of Medical Biochemistry, Dr. ALM-PGIBMS, University of Madras, Madras, India.
Balakumar P S S MurthyDepartment of Vascular and Endovascular Sciences, Tamilnadu Government Multi Super Speciality Hospital, Chennai, India.
Rif S El-MallakhDepartment of Psychiatry, University of Louisville School of Medicine, Louisville, KY, United States of America.
Ranga N ParthasarathyDepartment of Medical Biochemistry, Dr. ALM-PGIBMS, University of Madras, Madras, India.
Bhuvarahamurthy VenugopalDepartment of Medical Biochemistry, Dr. ALM-PGIBMS, University of Madras, Madras, India.ORCID 0000-0002-5073-4091
University of Louisville · USUniversity of Madras · INTamil Nadu Government Multi Super Speciality Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biallelic mutations in ACP5, encoding tartrate-resistant acid phosphatase (TRACP), have recently been identified to cause the inherited immuno-osseous disorder, spondyloenchondrodysplasia (SPENCD). This study was undertaken to characterize the eight reported missense mutations in ACP5 associated with SPENCD on TRACP expression. ACP5 mutant genes were synthesized, transfected into human embryonic kidney (HEK-293) cells and stably expressing cell lines were established. TRACP expression was assessed by cytochemical and immuno-cytochemical staining with a panel of monoclonal antibodies. Analysis of wild (WT) type and eight mutant stable cell lines indicated that all mutants lacked stainable enzyme activity. All ACP5 mutant constructs were translated into intact proteins by HEK-293 cells. The mutant TRACP proteins displayed variable immune reactivity patterns, and all drastically reduced enzymatic activity, revealing that there is no gross inhibition of TRACP biosynthesis by the mutations. But they likely interfere with folding thereby impairing enzyme function. TRACP exists as two isoforms. TRACP 5a is a less active monomeric enzyme (35kD), with the intact loop peptide and TRACP 5b is proteolytically cleaved highly active enzyme encompassing two subunits (23 kD and 16 kD) held together by disulfide bonds. None of the mutant proteins were proteolytically processed into isoform 5b intracellularly, and only three mutants were secreted in significant amounts into the culture medium as intact isoform 5a-like proteins. Analysis of antibody reactivity patterns revealed that T89I and M264K mutant proteins retained some native conformation, whereas all others were in "denatured" or "unfolded" forms. Western blot analysis with intracellular and secreted TRACP proteins also revealed similar observations indicating that mutant T89I is amply secreted as inactive protein. All mutant proteins were attacked by Endo-H sensitive glycans and none could be activated by proteolytic cleavage in vitro. In conclusion, determining the structure-function relationship of the SPENCD mutations in TRACP will expand our understanding of basic mechanisms underlying immune responsiveness and its involvement in dysregulated bone metabolism.

Indexed as

Mutation, MissenseAmino Acid SubstitutionAutoimmune DiseasesGlycosylationHumansMutant ProteinsOsteochondrodysplasiasProteolysisTartrate-Resistant Acid PhosphataseACP5 protein, humanMutant ProteinsTartrate-Resistant Acid Phosphatase

Identifiers

PMID32214327
PMCPMC7098635
OpenAlexW3013005308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.